Nutex Health에 대한 매도 수량은 투자자에게 Nutex Health의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Nutex Health (NASDAQ:NUTX) 주식, 공매도 수량 보고

Nutex Health

Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.

Market Recovery image

Opinion

Trading Ideas

ACHR

HNRG

NUTX

RGTI

RKLB

VNET

오늘은 유망한 기술적 추세가 주가 상승을 이끌고 있는 6가지 종목을 살펴보려고 한다. 벤징가 엣지에서 모멘텀 점수가 최소 98점 이상인 종목 중 향후 몇 주 동안 상승할 가능성이 있는 종목에 초점을 맞추고 있다.

미국 증시 반등 속 기술적 모멘텀 보이는 주식 6종목

Nutex Health Inc

Citigroup analyst Xiaopo Wei initiates coverage on Chagee Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHA#NASDAQ">CHA</a>) with a Buy rating and announces Price Target of $43.7.

News

Price Target

Initiation

Analyst Ratings

Citigroup Initiates Coverage On Chagee Holdings with Buy Rating, Announces Price Target of $43.7

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D").
The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.

Biotech

General

BDRX

Biodexa Announces Procurement Of First Patient In Phase 2 Study Of Tolimidone In Type 1 Diabetes

BKTI

BK Technologies To Join Russell 2000 And Russell 3000 Indexes

Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>) ("Nixxy" or the "Company"), an AI-powered data and communications infrastructure company, today announced the successful acquisition of the Leadnova.ai platform assets from the NexGenAI suite of companies. Nixxy also reported that it generated approximately $5.2 million in unaudited gross revenue for the month of May 2025 up from approximately $1.4 million in April 2025.

NIXX

Nixxy Acquires Leadnova.ai Platform Assets From NexGenAI Suite Of Companies; Nixxy Generates Gross Revenues Of About $5.2M In May 2025

GlobalFoundries Announces $16B Investment To Reshore Essential Chip Manufacturing And Accelerate AI Growth

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes ("T1D").
The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute. The study will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The study may be expanded in due course.

Biodexa Pharmaceuticals Announces First Patient Dosed In Phase 2 Investigator-Initiated Trial Of Tolimidone For Type 1 Diabetes At University Of Alberta, Evaluating Insulin And Glucose Markers Across Three Dose Groups with Potential For Study Expansion

Dollar Tree Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)&nbsp;stock is <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower during the premarket</a>&nbsp;after its first-quarter 2025 earnings report.
Net sales increased 11.3% to $4.6 billion, beating the consensus of $4.53 billion and the management guidance of $4.5 billion—$4.6 billion.
Same-store net sales increased 5.4%, driven by a 2.5% increase in traffic and a 2.8% <a target="_blank" href="https://www.benzinga.com/trading-ideas/previews/25/06/45754249/dollar-tree-q1-earnings-preview-can-the-discount-retailer-beat-and-raise-like-peer-dollar-general" rel="noreferrer noopener">increase in average ticket</a>, beating the management guidance growth of 3% – 5%.
6.4% consumables <a target="_blank" href="https://corporate.dollartree.com/_assets/_fb720ee9222d1724ca4693e29c9ff376/dollartreeinfo/db/857/11067/pdf/Dollar+Tree+Inc.+Q1+2025+IR+Supplemental+-+FINAL+AS+PUBLISHED.pdf" rel="noreferrer noopener">comp</a> and 4.6% discretionary comp – highest discretionary comp growth since Q4 2022.
On Wednesday, Dollar Tree reported adjusted earnings of $1.26 per share, beating the analyst estimate of $1.21, better than management expectation of $1.10 – $1.25.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44677660/the-new-bull-case-for-dollar-tree-raise-prices-boost-margins-blame-tariffs" rel="noreferrer noopener">Dollar Tree Surges Nearly 8% After Citi Upgrade: Analysts Say Tariffs Could Boost Margins, Not Hurt Them</a>
Gross profit increased 11.7% to $1.6 billion. The gross margin expanded 20 basis points to 35.6%, driven primarily by lower freight, improved mark-on, and lower occupancy costs due to sales leverage, partially offset by increased distribution, <a href="https://www.benzinga.com/pressreleases/25/06/b45766244/dollar-tree-inc-reports-results-for-the-first-quarter-fiscal-2025">shrink, and markdown costs</a>.
Adjusted operating income increased 1.4% to $387.8 million, and adjusted operating margin contracted 80 basis points to 8.4%.
In March, the company <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44491397/dollar-tree-q4-earnings-surpass-estimates-unloads-family-dollar-for-1b" rel="noreferrer noopener">agreed to sell</a> the Family Dollar business to Brigade and Macellum for $1.007 billion. Net proceeds are estimated to total approximately $800 million. Additionally, Dollar Tree expects the economic impact of tax benefits from losses on the sale to be approximately $350 million. The deal is expected to close in the second quarter of fiscal 2025.
Fiscal Outlook
Dollar Tree reaffirms <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44491397/dollar-tree-q4-earnings-surpass-estimates-unloads-family-dollar-for-1b" rel="noreferrer noopener">fiscal year 2025 sales&nbsp;guidance</a> of $18.5 billion—$19.11 billion versus a consensus of $18.95 billion, based on comparable store net sales growth of 3% to 5%.
The company said its outlook assumes the current tariff level remains in effect for the balance of the fiscal year and that it will be able to mitigate most of the incremental margin pressure from higher tariffs and other input costs.
The company raised its adjusted earnings guidance from $5.00-$5.50 per share to $5.15-$5.65 per share compared to analysts estimate of $5.21.
As Dollar Tree will bear the full year of the costs to support Family Dollar but only expects to receive offsetting reimbursement income in the second half of the year, the company&#8217;s full-year earnings will be negatively impacted by approximately 30 cents to 35 cents per share, with that impact concentrated in the first two quarters of the fiscal year.
Second Quarter 2025 Outlook
Given trends and expectations for the balance of the quarter, Dollar Tree expects Q2 comparable net sales growth to be towards the higher end of its full-year outlook range of 3% to 5%.
Over the balance of fiscal 2025, the company expects to mitigate the earnings impact of the cost pressures it faces, including higher tariffs.
In the near term, it expects to see some earnings volatility based on the timing of the various inputs and outputs to the company&#8217;s financial results.
The company expects that the second-quarter adjusted EPS from continuing operations could be down as much as 45% to 50% year-over-year before re-accelerating in the third and fourth quarters to meet its full-year earnings outlook.
On Tuesday, the company&#8217;s rival Dollar General Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) stock closed around 16% higher at $112.57 after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45746307/dollar-general-boosts-annual-outlook-despite-ongoing-tariff-uncertainty" rel="noreferrer noopener">first-quarter 2025 earnings</a>.
Dollar Tree updated its expectations for the year, primarily to reflect its outperformance in the first quarter and the tariff uncertainty. It now expects fiscal year 2025 sales growth of approximately 3.7% to 4.7%, compared to its previous expectation of approximately 3.4% to 4.4%.
Same-store sales growth is expected to be approximately 1.5% to 2.5%, compared to its previous expectation of approximately 1.2% to 2.2%
Price Action: DLTR shares traded higher by 3.10% at $69.22 in premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45756387/why-is-cancer-diagnostic-guardant-health-stock-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?</a></li>
</ul>

Earnings

Retail Sales

Movers

DLTR

Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs

Citigroup analyst David Lebowitz upgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Sell to Neutral and raises the price target from $83 to $129.

Upgrades

BPMC

Citigroup Upgrades Blueprint Medicines to Neutral, Raises Price Target to $129

<ul>
<li>Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market</li>
<li>Evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development</li>
<li>Cost-efficient approach&nbsp;enhances Conduit's pipeline while preserving full ownership of intellectual property and data, maximizing shareholder value</li>
<li>Synergistic combination therapies&nbsp;under evaluation could redefine treatment standards in veterinary and human applications</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 04, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit" or the "Company") today announced that it has entered into a joint development agreement with Manoira Corporation ("Manoira"), a privately held specialty animal health company specializing in proprietary reformulation technologies to create novel therapeutics for veterinary and livestock applications. Under the terms of the joint development agreement, Manoira will evaluate Conduit's AZD1656 and AZD5658, both clinical-stage glucokinase activators, in animal health indications, providing Conduit with high-value translational data across human and veterinary applications.
Manoira will focus its initial evaluation of AZD1656 in animal osteoarthritis, a common degenerative joint condition in companion animals, to generate preclinical data that will better inform Conduit's human clinical programs. Notably, early animal studies conducted by AstraZeneca suggest that glucokinase activators may have therapeutic potential in osteoarthritis1. In addition, Manoira plans to evaluate a novel combination of its patented CBDA co-crystal with AZD1656 and AZD5658 for the treatment for osteoarthritis in animals.
This cost-efficient collaboration allows Conduit to accelerate its understanding of AZD1656's mechanism of action, safety profile, and potential efficacy across species, while retaining 100% ownership of all data and intellectual property generated relating to AZD1656 and AZD5658 for human applications. The partnership not only enhances Conduit's core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary market, creating a dual-track value proposition for its shareholders. The parties will determine any future financial benefits and implications upon review of the results of the evaluations and how to proceed as a result of any such findings. Additionally, Manoira will evaluate AZD5658 for veterinary applications, expanding the utility of Conduit's glucokinase activator portfolio and supporting cross-species insight generation.

Conduit Pharmaceuticals And Manoira Announce Strategic Joint Development Agreement To Evaluate Glucokinase Activators AZD1656 And AZD5658 For Veterinary Use

LIPO

Lipella Pharmaceuticals Re-Signs Manufacturing Collaboration Agreement With Cook MyoSite For LP-310 Clinical Development

Management

Hallador Energy Company Appoints Todd Telesz As CFO

PAX's award-winning portable dry herb cannabis vaporizers now more broadly available through Greenlane's distribution platform

GNLN

Greenlane Renews Distribution Agreement With PAX

Gadolinium-160 is a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapies. &nbsp;
- Supply agreement is for four years' supply of enriched Gd-160, commencing in 2026, with an expected minimum contract value of $1 million per annum.
ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has recently entered into a supply agreement with Isotopia Molecular Imaging Ltd. related to the supply of enriched Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
This agreement addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumours, and other malignancies.
Under the agreement, ASP Isotopes will leverage its proprietary Quantum Enrichment technology to provide Isotopia with enriched Gd-160, a stable isotope essential for manufacturing Tb-161. The supply agreement is for four years' supply, commencing in 2026, with an expected minimum contract value of $1 million per annum.
The collaboration combines ASP Isotopes' expertise in large-scale isotope enrichment—previously demonstrated through its production of Ytterbium-176 (Yb-176)—with Isotopia's proven capabilities in commercial-scale medical isotope production. Isotopia has consistently manufactured Lutetium-177 (Lu-177) and maintained weekly Tb-161 production for its clinical trials over the past two years.
Paul Mann, CEO of ASP Isotopes, emphasized the agreement's significance: "By supplying Gd-160, we are eliminating a major bottleneck in the development of Tb-161 therapies. Our investment in enrichment technology positions us to support the radiopharmaceutical industry's growing demand for stable isotopes. This partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms."
Dr. Eli Shalom, CEO of Isotopia, highlighted Tb-161's therapeutic advantages: "Tb-161's dual mechanism of action, including Auger electron emissions, enables precise targeting of micro-metastases while minimizing damage to healthy tissues. This partnership ensures a reliable Gd-160 supply chain, allowing us to scale production and advance our Tb-161-labeled drug candidates toward commercialization. We produce in our site in Israel and shortly the production will start in our second site in Indianapolis in the US."
Tb-161's Auger electrons induce double-strand DNA breaks in cancer cells, offering potential advantages over Lu-177 and alpha-emitting isotopes. This precision aligns with the oncology field's shift toward targeted radiotherapeutics, which improve efficacy and reduce side effects. The agreement comes as global interest in radiopharmaceuticals surges, driven by their ability to deliver localized radiation therapy via tumour-seeking molecules.
It is expected that Gd-160 will be enriched using the Company's Quantum Enrichment process, a novel laser-based approach to enriching isotopes. The Gd-160 plant will be part of a large Quantum plant that the Company is in the process of designing and constructing. Additional isotopes that are expected to be enriched in this large-scale laser facility include Nickel-64, Zinc-68, Ytterbium-176, Barium-137, Ytterbium-171 and Lithium 6/7.
This partnership positions both companies at the forefront of the radiopharmaceutical revolution, with the potential to expand treatment options for cancer patients worldwide. The Company is in discussions with other customers who require Gd-160 and expects to sign additional orders during 2025

Contracts

ASPI

ASP Isotopes And Isotopia Enters Supply Agreement For Gadolinium-160 To Help Accelerate Terbium-161 Production For Advanced Cancer Therapies With Expected Minimum Contract Value Of $1M Per Year

PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), owner of brands such as Tommy Hilfiger and Calvin Klein, will release earnings results for the first quarter, after the closing<a href="https://www.benzinga.com/quote/PVH/earnings"> bell on Wednesday, June 4</a>.
Analysts expect the New York-based company to report quarterly earnings at $2.25 per share, down from $2.45 per share in the year-ago period. PVH projects to report quarterly revenue at $1.93 billion, compared to $1.95 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 30, Needham analyst Tom Nikic initiated coverage on PVH with a Buy rating. He gave the company a price target of $115.
With the recent buzz around PVH, some investors may be eyeing potential gains from the company's dividends too. Currently, PVH offers an annual dividend yield of 0.18%. That&#8217;s a quarterly dividend amount of 4 cents per share (15 cents a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $3,301,600 or around 40,000 shares. For a more modest $100 per month or $1,200 per year, you would need $660,320 or around 8,000 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.15 in this case). So, $6,000 / $0.15 = 40,000 ($500 per month), and $1,200 / $0.15 = 8,000 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
PVH Price Action: Shares of PVH gained 0.5% to close at $82.54 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Fell</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

How To Earn $500 A Month From PVH Stock Ahead Of Q1 Earnings

Citigroup analyst Ryan Levine downgrades Constellation Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) from Buy to Neutral and raises the price target from $232 to $318.

Downgrades

Citigroup Downgrades Constellation Energy to Neutral, Raises Price Target to $318

Legal

SGBX

Safe and Green Holdings Receives Court-Ordered Award Of More Than $1.1M For Attorney's Fees And Costs Part Of EDI Litigation

Editor&#8217;s note: This story was corrected to update the earnings estimates.
Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/b45757637/asana-announces-first-quarter-fiscal-2026-results">details from the report.&nbsp;</a>
The Details: Asana reported quarterly earnings of five cents per share, which beat the Street estimate of two cents. Quarterly revenue of $187.27 million exceeded the consensus estimate of $185.4 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
For the first quarter of fiscal 2026, Asana reported: 
<ul class="wp-block-list">
<li>The number of Core customers, or customers spending $5,000 or more on an annualized basis, grew to 24,297, an increase of 10% year-over-year. Revenues from Core customers grew 10% year-over-year.</li>
<li>The number of customers spending $100,000 or more on an annualized basis grew to 728, an increase of 20%.</li>
<li>Overall dollar-based net retention rate was 95%.</li>
</ul>
&#8220;Just months after launching AI Studio, we&#8217;ve already crossed $1 million in ARR and head into Q2 with a robust, rapidly growing global pipeline,&#8221; said Dustin Moskovitz, CEO of Asana. 
&#8220;With new offerings like the AI Studio Plus package, and Smart Workflow Gallery, we&#8217;re making these transformative AI capabilities even more accessible,&#8221; Moskovitz added. 
Outlook:&nbsp;Asana sees second-quarter adjusted earnings of four cents to five cents per share, versus the four cent estimate, and revenue in a range of $192 million to $194 million, versus the&nbsp;$192.19 million&nbsp;analyst estimate.
Asana raised its fiscal 2026 adjusted EPS guidance from a range of 19 cents to 20 cents to 22 cents, versus the 33 cent estimate, and widened its revenue outlook from a range of $782 million to $790 million&nbsp;to&nbsp;a new range of $775 million to $790 million, versus the&nbsp;$857.76 million&nbsp;estimate.
ASAN Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Asana stock was down 12% at $16.69 in Wednesday's premarket trading. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Tech

ASAN

Asana Reports Q1 Earnings: Earnings, Revenues Beat (CORRECTED)

Citigroup analyst Marta Romero reinstates Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) with a Buy.

Citigroup Reinstates Buy on Banco Santander

Elon Musk said on the campaign trail that he would <a href="https://www.benzinga.com/startups/25/01/43391017/2-trillion-by-2026-elon-musks-ambitious-push-to-reinvent-government-spending-with-silicon-valley-powerhouses">slash $2 trillion from the federal budget</a>. Then it became $1 trillion. Then $150 billion. According to Steve Bannon, it&#8217;s now effectively nothing. "None of this makes sense," Bannon said during the <a href="https://www.youtube.com/watch?v=dHI2Vn0hPa0">Semafor World Economy Summit</a> in April, criticizing Musk's Department of Government Efficiency project for falling far short of its ambitious promises.
<h2 class="wp-block-heading">Bannon Doubts Real Savings</h2>
Bannon, a former chief strategist to President Donald Trump, said that although Musk arrived in Washington, D.C. with a bold plan, the results were minimal. "He went from $2 trillion a year to $1 trillion a year to $150 billion next year with nothing this year," Bannon said. &#8220;We need to know exactly what he found as far as fraud goes.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Bannon demanded &#8220;specific accounting&#8221; of the DOGE program's work, suggesting that despite Musk's intentions, the effort to cut waste and fraud has lacked real substance. "Treasury's got to sign off, [the Office of Management and Budget] has got to sign off. Every department head. We have to have a letter of certification that not one data set or piece of data&#8230; are held by anyone except the Trump administration and the U.S. Government," he said.
When asked whether he trusts Musk not to misuse government data, Bannon replied: "Trust but verify."
Musk has officially stepped down from DOGE, concluding a 130-day tenure as a "special government employee." In a <a href="https://x.com/elonmusk/status/1927877957852266518">post</a> on his social media platform X on Thursday, Musk expressed gratitude to Trump for the opportunity to reduce wasteful government spending, saying, &#8220;The @DOGE mission will only strengthen over time as it becomes a way of life throughout the government.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
<h2 class="wp-block-heading">Numbers Don't Add Up</h2>
<a href="https://www.theatlantic.com/politics/archive/2025/05/musk-doge-spending-cuts/682736/">The Atlantic</a> reported that DOGE's actual verified budget savings totaled just $2 billion, a far cry from the $165 billion the agency claimed at the time of its analysis in early May. According to the report, the project has been plagued by <a href="https://www.benzinga.com/government/regulations/25/05/45466451/elizabeth-warren-torches-doges-social-security-fraud-claims-pointing-at-internal-memo-discovery-says-elon-musk-jd-vance-and-trump-are-lying">false savings</a>, repeated counting of the same cuts, and expired contracts being listed as fresh reductions. Musk&#8217;s team once <a href="https://www.benzinga.com/news/25/03/44065790/elon-musks-government-overhaul-faces-revolt-even-from-trumps-own-officials">claimed $8 billion in savings</a> from ending an $8 million contract.
&#8220;If you thought DOGE was really about cutting costs, you weren't in on the joke,&#8221; The Atlantic concluded.
Even Musk himself has admitted it didn't go as planned. In an interview with the <a href="https://www.washingtonpost.com/business/2025/05/27/elon-musk-spacex-starship-doge/">Washington Post</a> recently, he said, "The federal bureaucracy situation is much worse than I realized." He acknowledged DOGE had become a political scapegoat: "DOGE is just becoming the whipping boy for everything."
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Frustration On All Sides
Musk also expressed disappointment with Trump's signature spending package, the so-called "Big Beautiful Bill," telling <a href="https://www.youtube.com/watch?v=fLbx2PJ4pqE">CBS News</a>: "I was disappointed to see the massive spending bill, frankly, which increases the budget deficit, not just decreases it, and undermines the work that the DOGE team is doing."
For Bannon, the project's failure underscores the need for structural reform and transparency. He insisted the country is running out of time to fix its finances. "Our choices narrow every day," he said. "The current system is not sustainable."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
Image: Shutterstock

Steve Bannon Says Elon Musk's DOGE Cuts Went From $2 Trillion To $150 BilSteve Bannon Says Elon Musk's DOGE Cuts Went From $2 Trillion To $150 Billion And Now Nothing—'None Of This Makes Sense'

Guggenheim analyst Ali Faghri downgrades Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Buy to Neutral.

APTV

Guggenheim Downgrades Aptiv to Neutral

Press Releases

Nutex Health Hospitals Earn Multiple Community Honors and Awards in Q4

Nutex Health Issues No Surprises Act (NSA) Arbitration Update

NUTEX HEALTH SCHEDULES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RELEASE AND CONFERENCE CALL

Nutex Health to Present at the EDPMA Solutions Summit 2025

NUTEX HEALTH RESCHEDULES EARNINGS RELEASE AND CONFERENCE CALL

NUTEX HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

Nutex Health Schedules 2025 First Quarter Financial Results Release and Conference Call

Entertainment

Small Cap

NUTEX HEALTH REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF GRANT THORNTON LLP AS ITS INDEPENDENT AUDITOR

NUTEX HEALTH ANNOUNCES INTERNET AVAILABILITY OF PROXY MATERIALS FOR ITS 2025 ANNUAL MEETING

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Nutex Health

매도 수량

Nutex Health (NASDAQ:NUTX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌